New Treatment for Diabetic Macular Edema

Original Video: Channel Nine News

From November 1 2016, a new, sustained-release eye implant, Dexamethasone, will become available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of Diabetic Macular Edema (DME).


DME occurs when the damaged blood vessels leak fluid and fatty deposits into the macula area, the central part of the retina. The fluid makes the macula swell and become water-logged, which blurs vision. To treat DME, an Intravitreal injection is used to decrease swelling and stabilise vision.


The Dexamethasone biodegradable eye implant is designed to provide sustained delivery, which may reduce treatments to one injection every 4-6 months.


Dexamethasone is the first corticosteroid to be PBS listed for diabetic macular edema, providing a practical treatment alternative for patients where previous treatments are unsuccessful.


Please discuss with our retina specialists who will be able to determine if this treatment is appropriate for you.